Antenatal magnesium sulphate exposure is associated with prolonged parathyroid hormone suppression in preterm neonates

Acta Paediatr. 2001 Mar;90(3):278-81.

Abstract

The effects of maternal magnesium sulphate treatment on neonatal mineral status and parathyroid hormone secretory response were studied in 8 exposed and 27 control preterm infants during the first 2 wk of life. Antenatal magnesium sulphate resulted in hypermagnesaemia during the first 3-7 d of life without affecting other serum mineral concentrations.

Conclusion: Early hypermagnesaemia was associated with hypercalciuria during the first 3 d and parathyroid hormone suppression up to the age of 2 wk in the exposed infants.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Calcium / blood
  • Calcium / urine
  • Female
  • Fetal Blood / chemistry
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Magnesium / blood
  • Magnesium / urine
  • Magnesium Sulfate / adverse effects*
  • Magnesium Sulfate / therapeutic use
  • Parathyroid Hormone / blood
  • Parathyroid Hormone / deficiency*
  • Phosphorus / blood
  • Phosphorus / urine
  • Pre-Eclampsia / drug therapy
  • Pregnancy
  • Tocolytic Agents / adverse effects*
  • Tocolytic Agents / therapeutic use
  • Trace Elements / blood*
  • Trace Elements / urine

Substances

  • Parathyroid Hormone
  • Tocolytic Agents
  • Trace Elements
  • Phosphorus
  • Magnesium Sulfate
  • Magnesium
  • Calcium